References
- Melichar, B.; Nash, M A.; Lenzi, R.; Platsoucas, C D.; Freedman, R S. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3 + tumour-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis.Clin. Exp. Immunol. 2000, 119, 19–27. [PUBMED], [INFOTRIEVE], [CSA]
- Loercher, A E.; Nash, M A.; Kavanagh, J J.; Platsoucas, C D.; Freedman, R S. Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells.J. Immunol. 1999, 163, 6251–6260. [PUBMED], [INFOTRIEVE], [CSA]
- Berek, J S.; Bast, R C., Jr.; Lichtenstein, A.; Hacker, N F.; Spina, C A.; , et al. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer.Obstet. Gynecol. 1984, 64, 708–714. [PUBMED], [INFOTRIEVE], [CSA]
- Chen, C K.; Wu, M Y.; Chao, K H.; Ho, H N.; Sheu, B C.; Sheu, B C.; Huang, S C. T lymphocytes and cytokine production in ascitic fluid of ovarian malignancies.J. Formos. Med. Assoc. 1999, 98, 24–30. [PUBMED], [INFOTRIEVE], [CSA]
- Markowska, J.; Lachi, J K.; Jaroszewski, J.; Wiktorowicz, K. The usefulness of CD4/CD8 ratio evaluation in monitoring of ovarian cancer patients.Eur. J. Gynaecol. Oncol. 1995, 16, 54–58. [PUBMED], [INFOTRIEVE], [CSA]
- Richters, C D.; Burger, C W.; van de Loosdrecht, A A.; van Rijswijk, R E.; Calame, W.; , et al. The cellular composition in the peritoneal cavity and the cytotoxic function of the peritoneal cells from patients with ovarian cancer; effect of tumor necrosis factor-alpha treatment.Cancer Lett. 1993, 68, 25–31. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Eisenthal, A.; Polyvkin, N.; Bramante-Schreiber, L.; Misonznik, F.; Hassner, A.; Lifschitz-Mercer, B. Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer.Human Pathol. 2001, 32, 803–807. [CSA], [CROSSREF]
- Iwamoto, M.; Shinohara, H.; Miyamoto, A.; Okuzawa, M.; , et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas.Int. J. Cancer 2003, 104, 92–97. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Inoue, K.; Yamashita, A.; Yamashita, M.; Morioka, M.; Fujita, Y.; Terao, N. Distribution of S-100 protein-positive dendritic cells inside the cancer nest and expression of HLA-DR antigen and blood group antigen on the cancer cell in transitional cell carcinoma of the urinary bladder-in relation to tumor progression and prognosis.Nippon Hinyokika Gakkai Zasshi 1994, 85, 495–503. [PUBMED], [INFOTRIEVE], [CSA]
- Zavadova, E.; Savary, C A.; Templin, S.; Verschraegen, C F.; Freedman, R S. Maturation of dendritic cells from ovarian cancer patients.Cancer Chemother. Pharmacol. 2001, 48, 289–296. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Melichar, B.; Savary, C.; Kudelka, A P.; Verschraegen, C.; Kavanagh, J J.; , et al. Lineage-negative human leukocyte antigen-DR + cells with the phenotype of undifferentiated dendritic cells in patients with carcinoma of the abdomen and pelvis.Clin. Cancer Res. 1998, 4, 799–809. [PUBMED], [INFOTRIEVE], [CSA]
- Santin, A D.; Bellone, S.; Ravaggi, A.; Roman, J.; Smith, C V.; Pecorelli, S.; Cannon, M J.; Parham, G P. Increased levels of interleukin-10 and transforming growth factor-beta in the plasma and ascitic fluid of patients with advanced ovarian cancer.BJOG 2001, 108, 804–808. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kryczek, I.; Grybos, M.; Karabon, L.; Klimczak, A.; Lange, A. IL-6 production in ovarian carcinoma is associated with histiotype and biological characteristics of the tumour and influences local immunity.Br. J. Cancer 2000, 82, 621–628. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Fujita, T.; Miyamoto, S.; Onoyama, I.; Sonoda, K.; Mekada, E.; Nakano, H. Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer.Cancer Lett. 2003, 192, 161–169. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Yabushita, H.; Shimazu, M.; Noguchi; Kishida, T.; Narumiya, H.; Sawaguchi, K.; Noguchi, M. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.Oncol. Rep. 2003, 10, 89–95. [PUBMED], [INFOTRIEVE], [CSA]
- Santin, A D.; Hermonat, P L.; Ravagge, A.; Cannon, M J.; Pecorelli, S.; Parham, G P. Secretion of vascular endothelial growth factor in ovarian cancer.Eur. J. Gynaecol. Oncol. 1999, 20, 177–181. [PUBMED], [INFOTRIEVE], [CSA]
- Molica, S.; Vacca, A.; Ribatti, D.; Cuneo, A.; Cavazzini, F.; , et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia.Blood 2002, 100, 3344–3351. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Candido Dos Reis, F J.; Moreira de Andrade, J.; Bighetti, S. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors.Gynecol. Obstet. Invest. 2002, 54, 132–136. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kaneko, T.; Konno, H.; Baba, M.; Tanaka, T.; Nakamura, S. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.Cancer Sci. 2003, 94, 43–49. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Alexandrakis, M G.; Passam, F H.; Boula, A.; Christophoridou, A.; Aloizos, G.; Roussou, P.; Kyriakou, D S. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.Ann. Hematol. 2003, 82, 19–23. [PUBMED], [INFOTRIEVE], [CSA]
- Manders, P.; Beex, L V.; Tjan-Heijnen, V C.; Geurts-Moespot, J.; Van Tienoven, T H.; Foekens, J A.; Sweep, C G. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy.Br. J. Cancer 2002, 87, 772–778. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Ohm, J E.; Carbone, D P. VEGF as a mediator of tumor-associated immunodeficiency.Immunol. Res. 2001, 23, 263–272. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Young, M R.; Petruzzelli, G J.; Kolesiak, K.; Achille, N.; Lathers, D M.; Gabrilovich, D I. Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34 (+) progenitor cells.Hum. Immunol. 2001, 62, 332–341. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Oyama, T.; Ran, S.; Ishida, T.; Nadaf, S.; Kerr, L.; Carbone, D P.; Gabrilovich, D I. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells.J. Immunol. 1998, 160, 1224–1232. [PUBMED], [INFOTRIEVE], [CSA]
- Ohm, J E.; Gabrilovich, D I.; Sempowski, G D.; Kisseleva, E.; Parman, K S.; Nadaf, S.; Carbone, D P. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.Blood 2003, 101, 4878–4886. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Inoshima, N.; Nakanishi, Y.; Minami, T.; Izumi, M.; Takayama, K.; Yoshino, I.; Hara, N. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer.Clin. Cancer Res. 2002, 8, 3480–3486. [PUBMED], [INFOTRIEVE], [CSA]
- Takahashi, A.; Kono, K.; Itakura, J.; Amemiya, H.; Feng Tang, R.; , et al. Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer.Oncology 2002, 62, 121–127. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Gabrilovich, D.; Ishida, T.; Oyama, T.; Ran, S.; Kravtsov, V.; Nadaf, S.; Carbone, D P. Vascular endothelial growth factor inhibits the demelopment of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.Blood 1998, 92, 4150–4166. [PUBMED], [INFOTRIEVE], [CSA]
- Hamai, J.; Yakushiji, M.; Miyahara, K.; Okura, N.; Tazaki, T.; Nishimura, H.; Kato, T. Studies of immunological function in patients with ovarian cancer.Nippon Sanka Fujinka Gakkai Zasshi 1985, 37, 1875–1882. [PUBMED], [INFOTRIEVE], [CSA]
- Zou, W.; Machelon, V.; Coulomb-L'Hermin, A.; Borvak, J.; Nome, F.; , et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.Nat. Med. 2001, 7, 1339–1346. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Yang, A S.; Lattime, E C. Tumor-induced interleukin 10 suppresses the ability of splenic dendritic cells to stimulate CD4 and CD8 T-cell responses.Cancer Res. 2003, 63, 2150–2157. [PUBMED], [INFOTRIEVE], [CSA]
- Buelens, C.; Verhasselt, V.; De Groote, D.; Thielemans, K.; Goldman, M.; Willems, F. Interleukin-10 prevents the generation of dendritic cells from human peripheral blood mononuclear cells cultured with interleukin-4 and granulocyte/macrophage-colony-stimulating factor.Eur. J. Immunol. 1997, 27, 756–762. [PUBMED], [INFOTRIEVE], [CSA]
- Menetrier-Caux, C.; Montmain, G.; Dieu, M C.; Bain, C.; , et al. Inhibition of the differentiation of dendritic cells from CD34 (+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor.Blood 1998, 92, 4778–4791. [PUBMED], [INFOTRIEVE], [CSA]